Therapeutic Class

Pfizer: Trial management and manufacturing key to DMD gene therapy success

Therapeutic Class

Pfizer: Trial management and manufacturing key to DMD gene therapy success Pfizer: Trial management and manufacturing key to DMD gene therapy success

Pfizer has stressed the importance of having the right manufacturing capabilities ato support its gene therapy for DMD.

byDan Stanton, Editorial director

Sep 16, 2021

|

1 Min Read

Flash drive: French CDMO to scale up viral vector production

Facilities & Capacity

Flash drive: French CDMO to scale up viral vector production Flash drive: French CDMO to scale up viral vector production

Sep 14, 2021

1 Min Read

Seqirus looks to next-gen mRNA for seasonal flu vaccine

Therapeutic Class

Seqirus looks to next-gen mRNA for seasonal flu vaccine Seqirus looks to next-gen mRNA for seasonal flu vaccine

Aug 31, 2021

1 Min Read

eBook: Cell and Gene Therapies — <br>A 2021 Industry Update

Therapeutic Class

eBook: Cell and Gene Therapies — A 2021 Industry Update eBook: Cell and Gene Therapies — A 2021 Industry Update

byDan Stanton, Gareth Macdonaldand 2 more

Aug 25, 2021

Polyplus reagent aims to ease CGT manufacturing issues

Upstream & Downstream Processing

Polyplus reagent aims to ease CGT manufacturing issues Polyplus reagent aims to ease CGT manufacturing issues

byMillie Nelson

Aug 18, 2021

1 Min Read

Podcast: GSK’s digital twin approach to vaccine development

Therapeutic Class

Podcast: GSK’s digital twin approach to vaccine development Podcast: GSK’s digital twin approach to vaccine development

Aug 10, 2021

1 Min Read

Second Bluebird gene therapy approval a boon for Minaris

Therapeutic Class

Second Bluebird gene therapy approval a boon for Minaris

Second Bluebird gene therapy approval a boon for Minaris

byDan Stanton, Editorial director

Sanofi doubles down on mRNA vaccines with $475m annual booster shot

Therapeutic Class

Sanofi doubles down on mRNA vaccines with $475m annual booster shot

Sanofi doubles down on mRNA vaccines with $475m annual booster shot

byDan Stanton, Editorial director

$250m CAR-T startup ‘validates’ Intellia’s allogeneic and CRISPR platforms

Therapeutic Class

$250m CAR-T startup ‘validates’ Intellia’s allogeneic and CRISPR platforms

$250m CAR-T startup ‘validates’ Intellia’s allogeneic and CRISPR platforms

byDan Stanton, Editorial director

Vectorized antibody startup VectorY to establish Dutch plant

Therapeutic Class

Vectorized antibody startup VectorY to establish Dutch plant

Vectorized antibody startup VectorY to establish Dutch plant

byDan Stanton, Editorial director

Enzymatic DNA printer will speed R&D and COVID testing, says DNA Script

Upstream & Downstream Processing

Enzymatic DNA printer will speed R&D and COVID testing, says DNA Script

Enzymatic DNA printer will speed R&D and COVID testing, says DNA Script

byGareth Macdonald

Dendreon leveraging Provenge network to launch cell therapy CDMO biz

Facilities & Capacity

Dendreon leveraging Provenge network to launch cell therapy CDMO biz

Dendreon leveraging Provenge network to launch cell therapy CDMO biz

byDan Stanton, Editorial director

Get your TOX off: Piramal looks to next generation of ADCs

Therapeutic Class

Get your TOX off: Piramal looks to next generation of ADCs

Get your TOX off: Piramal looks to next generation of ADCs

byDan Stanton, Editorial director

Robotic CAR? Cytiva and Multiply team on cell therapy automation

Upstream & Downstream Processing

Robotic CAR? Cytiva and Multiply team on cell therapy automation

Robotic CAR? Cytiva and Multiply team on cell therapy automation

byDan Stanton, Editorial director

UPenn gene therapy researchers lease space at Discovery Labs

Facilities & Capacity

UPenn gene therapy researchers lease space at Discovery Labs

UPenn gene therapy researchers lease space at Discovery Labs

byGareth Macdonald

eBook: ADCs — Evolving Links in the Biopharmaceutical Pipeline

eBook: ADCs — Evolving Links in the Biopharmaceutical Pipeline

eBook: ADCs — Evolving Links in the Biopharmaceutical Pipeline

byDan Stanton, Managing editor

Thermo teams with UCSF on San Fran cell therapy center

Facilities & Capacity

Thermo teams with UCSF on San Fran cell therapy center

Thermo teams with UCSF on San Fran cell therapy center

byGareth Macdonald

Laronde aims to turn cells into drug production facilities using eRNA

Therapeutic Class

Laronde aims to turn cells into drug production facilities using eRNA

Laronde aims to turn cells into drug production facilities using eRNA

byGareth Macdonald

Podcast: On board the Cell Shuttle with Cellares

Therapeutic Class

Podcast: On board the Cell Shuttle with Cellares

Podcast: On board the Cell Shuttle with Cellares

byDan Stanton, Editorial director

Allogene and Regenxbio point to inhouse CGT advantage

Facilities & Capacity

Allogene and Regenxbio point to inhouse CGT advantage

Allogene and Regenxbio point to inhouse CGT advantage

byDan Stanton, Editorial director

Charles River sets sights on cell therapy manufacturing after Cognate buy

Therapeutic Class

Charles River sets sights on cell therapy manufacturing after Cognate buy

Charles River sets sights on cell therapy manufacturing after Cognate buy

byGareth Macdonald

ADC Therapeutics joins conjugate elite with Zynlonta FDA approval

ADC Therapeutics joins conjugate elite with Zynlonta FDA approval

ADC Therapeutics joins conjugate elite with Zynlonta FDA approval

byDan Stanton, Editorial director

Biosimilars: Roche and Biogen talk competition, price, opportunities

Biosimilars: Roche and Biogen talk competition, price, opportunities

Biosimilars: Roche and Biogen talk competition, price, opportunities

byGareth Macdonald

Bayer confirms $200m Berkeley cell therapy facility

Facilities & Capacity

Bayer confirms $200m Berkeley cell therapy facility

Bayer confirms $200m Berkeley cell therapy facility

byDan Stanton, Editorial director

Autologous therapy firms should use tech to cut COGS, says expert

Therapeutic Class

Autologous therapy firms should use tech to cut COGS, says expert

Autologous therapy firms should use tech to cut COGS, says expert

byGareth Macdonald

Podcast: The future of cell and gene therapies

Therapeutic Class

Podcast: The future of cell and gene therapies

Podcast: The future of cell and gene therapies

byDan Stanton, Editorial director

Moderna trialing refrigerator stable COVID-19 vaccine

Bioprocess Insider

Moderna trialing refrigerator stable COVID-19 vaccine

Moderna trialing refrigerator stable COVID-19 vaccine

byMillie Nelson, Editor

Oxford Biomedica working to optimize vector production platform

Upstream & Downstream Processing

Oxford Biomedica working to optimize vector production platform

Oxford Biomedica working to optimize vector production platform

byGareth Macdonald

Preparation key to gene therapy commercialization, MilliporeSigma

Therapeutic Class

Preparation key to gene therapy commercialization, MilliporeSigma

Preparation key to gene therapy commercialization, MilliporeSigma

byGareth Macdonald

Tenaya talks advantages of inhouse capabilities for CGT firms

Facilities & Capacity

Tenaya talks advantages of inhouse capabilities for CGT firms

Tenaya talks advantages of inhouse capabilities for CGT firms

byDan Stanton, Editorial director

Ori and ATMPS team to lower advanced therapy COGS through blockchain

Ori and ATMPS team to lower advanced therapy COGS through blockchain

Ori and ATMPS team to lower advanced therapy COGS through blockchain

byDan Stanton, Editorial director

CRISPR lauds easy scale-out of autologous sickle cell therapy

Facilities & Capacity

CRISPR lauds easy scale-out of autologous sickle cell therapy

CRISPR lauds easy scale-out of autologous sickle cell therapy

byDan Stanton, Editorial director

CGT firms making progress but manufacturing remains a hurdle, says analyst

Therapeutic Class

CGT firms making progress but manufacturing remains a hurdle, says analyst

CGT firms making progress but manufacturing remains a hurdle, says analyst

byGareth Macdonald

Singapore site sets Sanofi’s vaccine spend at beyond $2bn

Facilities & Capacity

Singapore site sets Sanofi’s vaccine spend at beyond $2bn

Singapore site sets Sanofi’s vaccine spend at beyond $2bn

byDan Stanton, Editorial director

Sterling makes good on ADC Biotechnology buy

Sterling makes good on ADC Biotechnology buy

Sterling makes good on ADC Biotechnology buy

byDan Stanton, Editorial director

Subscribe to receive our monthly print or digital publication

Join our 70,000+ readers. And yes, it's completely free.